TWI377949B - A chinese herb extract for treating dementia and preparation method thereof - Google Patents

A chinese herb extract for treating dementia and preparation method thereof Download PDF

Info

Publication number
TWI377949B
TWI377949B TW97122258A TW97122258A TWI377949B TW I377949 B TWI377949 B TW I377949B TW 97122258 A TW97122258 A TW 97122258A TW 97122258 A TW97122258 A TW 97122258A TW I377949 B TWI377949 B TW I377949B
Authority
TW
Taiwan
Prior art keywords
extract
polygonum multiflorum
solution
dementia
column
Prior art date
Application number
TW97122258A
Other languages
Chinese (zh)
Other versions
TW200950795A (en
Inventor
Rey Yuh Wu
Tzung Hsien Lai
Chia Yu Yen
Yau Jan Chyan
Original Assignee
Dev Center Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dev Center Biotechnology filed Critical Dev Center Biotechnology
Priority to TW97122258A priority Critical patent/TWI377949B/en
Publication of TW200950795A publication Critical patent/TW200950795A/en
Application granted granted Critical
Publication of TWI377949B publication Critical patent/TWI377949B/en

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

1377949 九、發明說明: 【發明所屬之技術領域】 本發明係關於—種中藥萃取物及其製備方法。本發明亦 :;1於萃取物及活性部分用於治療或預防諸如阿兹海默氏症 • (Alzheimer,s disease)之癡呆症的用途。 ' 【先前技術】 癡呆症為由超出正常老化所預期之腦損傷或疾病所引起 ㈣知功能之進行性下降。最熟知類型之癡呆症為阿兹海 默氏症。 ' 阿兹海默氏症(AD)為日益普遍之神經退化形式,在㈣ 以上之:人中其佔癡呆症之總病例的約50%-60%。由於人口 、’中老齡人之相對增加,估計全世界約有2.4億人受其影 響。在接下來之20至30年内其盛行率可能會增加。八〇為 一種進行性病症,其在臨床症狀發作與死亡之間約有8 5 年之平均持續時間。在與較高智力功能有關之腦部中角錐 Φ 形神經元之死亡及神經元突觸之缺失導致典型症狀,其特 … 徵為認知功能之總體及進行性障礙(參見Francis,P· 丁.等 人,J. Neuro1. Neur〇surg. pSyChiatry (1999) 66: 137- 147)。阿茲海默氏症臨床徵兆的特徵為進行性認知能力退 ' 化,以及每日生活之活動性下降及神經精神症狀或行為變 化° 在神經病理學上,AD之主要標誌為存在兩種特徵病 .¥ .類澱粉老年斑及神經原纖維纏結(NFT)。斑塊係於神 經兀外沈積,而纏結係在死後之腦中神經元内觀察到。類 U5989.doc 1377949 澱粉斑塊核心之一種主要組份為病理沈積之小類澱粉·β_肽 (Αβ),其係藉由分泌酵素自類澱粉前驅蛋白(Αρρ)裂解(參 見 Selkoe,D.J.,hv. (2001) 81: 741-766 ; Hardy, J·及 Selkoe,D.J·,Sciewce (2002) 297: 353-356)。Αβ,一種 ; 39_43殘基(MW約4 kDa)之自凝集肽,係合成為較大app " (11(M2〇 kDa)之部分。ApP為第I型整合膜醣蛋白,其具有1377949 IX. DESCRIPTION OF THE INVENTION: TECHNICAL FIELD OF THE INVENTION The present invention relates to a traditional Chinese medicine extract and a preparation method thereof. The invention also has the use of the extract and the active moiety for the treatment or prevention of dementia such as Alzheimer's disease. [Prior Art] Dementia is caused by brain damage or disease that is expected beyond normal aging. (4) Progressive decline in knowledge. The most well-known type of dementia is Alzheimer's disease. 'Alzheimer's disease (AD) is an increasingly common form of neurodegenerative disease, in more than (4): humans account for about 50%-60% of the total cases of dementia. Due to the relative increase in population and age among the elderly, it is estimated that about 240 million people around the world are affected. Its prevalence may increase over the next 20 to 30 years. Gossip is a progressive condition with an average duration of approximately 85 years between the onset of clinical symptoms and death. In the brain associated with higher intellectual function, the death of pyramidal Φ-shaped neurons and the loss of neuronal synapses lead to typical symptoms, which are characterized by general and progressive impairment of cognitive function (see Francis, P. Ding. Et al., J. Neuro1. Neur〇surg. pSyChiatry (1999) 66: 137-147). The clinical signs of Alzheimer's disease are characterized by progressive cognitive decline, as well as decreased daily activity and neuropsychiatric symptoms or behavioral changes. In neuropathology, the main hallmark of AD is the presence of two characteristic diseases. .¥. Starch-like age spots and neurofibrillary tangles (NFT). The plaque is deposited outside the nerves of the sac, and the tangles are observed in the neurons in the brain after death. Class U5989.doc 1377949 A major component of the amyloid plaque core is the pathologically deposited small starchy beta-peptide (Αβ), which is cleaved from the starch-like precursor protein (Αρρ) by secreting enzymes (see Selkoe, DJ, Hv. (2001) 81: 741-766; Hardy, J. and Selkoe, DJ., Sciewce (2002) 297: 353-356). Αβ, a self-aggregating peptide of 39_43 residues (MW about 4 kDa), synthesized as part of the larger app " (11(M2〇 kDa). ApP is a type I integral membrane glycoprotein with

•大的N_末端細胞外域、單跨膜區及短的細胞質尾區。Αβ區 位於ΑΡΡ之細胞外及跨臈區部分。ΑΡΡ參與AD中之神經元 細胞死亡之最常見假說為類澱粉蛋白假說。此假說假定斑 塊類澱粉沈積或部分凝集之可溶性Αβ引起一連串的神經毒 性,藉此導致與AD病理相似之神經退化(參見Se⑴〇e,D J.’ (2001) 81: 741-766 ; Hardy,J_ 及 Selkoe,D. J.,Sczewe (2002) 297: 353-356)。 目前可獲得之藥物可有助於減輕阿茲海默氏症之症狀, 但其不可改變其根本的病理過程。阿茲海默氏症通常無法 • 治癒。目前仍需要提供治療及/或預防年齡相關之癡呆 一 症、尤其阿茲海默氏症的方法。 何首烏㈣卿通常亦稱為首烏⑽⑽ wu > he shou wu . f〇-ti , f〇.ti.teng , Ch.nese kn〇tweed ^ climbing knotweed、fl〇wery kn〇tweed、⑸叫及其 類似名稱n -位名為何首烏之中國男子為此草藥有 記載的第-個食用《,其活至132歲。何首烏塊根傳統上 在中樂中用作滋補及抗老化藥物,尤其用於脫髮及頭髮早 何首烏味吉、甘且澀,且當攝取時具有輕微溫熱效 I15989.doc 1377949• Large N-terminal extracellular domain, single transmembrane region and short cytoplasmic tail region. The Αβ region is located outside the extracellular and trans-sacral regions of the sputum. The most common hypothesis that ΑΡΡ participates in neuronal cell death in AD is the amyloid-like hypothesis. This hypothesis assumes that plaque-like starch deposition or partially agglutinated soluble Αβ causes a cascade of neurotoxicity, thereby leading to neurodegeneration similar to AD pathology (see Se(1)〇e, D J.' (2001) 81: 741-766; Hardy , J_ and Selkoe, DJ, Sczewe (2002) 297: 353-356). Currently available drugs can help alleviate the symptoms of Alzheimer's disease, but they cannot change the underlying pathological process. Alzheimer's disease usually cannot be cured. There is still a need to provide a method of treating and/or preventing age-related dementia, particularly Alzheimer's disease. He Shouwu (4) Qing is also commonly known as Shouwu (10) (10) wu > he shou wu . f〇-ti , f〇.ti.teng , Ch.nese kn〇tweed ^ climbing knotweed, fl〇wery kn〇tweed, (5) called and similar Name n - The name of the Chinese man of Shouwu is the first food to be recorded for this herb, and it lives to 132 years old. Polygonum multiflorum is traditionally used as a nourishing and anti-aging drug in Chinese music, especially for hair loss and hair early. Shouwuweiji, Ganzi, and sputum, and has a slight warming effect when ingested I15989.doc 1377949

應:、可用作主藥或滋補藥物 < 主要組份。何首烏之主要 為/可南Λ州、四川、湖南、山東等地。根據令國文 獻W用何首烏之最早記錄可上溯至漢朝(206 B.C.-220 A.D.)。 何首烏之萃取物已被證明具有延長二倍體細胞之生命週 /月延長果蠅及老齡鵜鹕之壽命,降低超氧化物歧化酶 (SOD)之3量及活性且增強老化生物體中之修復能力 的功政(Vag 専尺,w〇Hd Science andShould:, can be used as a main drug or nourishing drug < main components. The main factors of Polygonum multiflorum are / can be Nanzhou, Sichuan, Hunan, Shandong and other places. According to the earliest record of the use of Polygonum multiflorum, the Chinese version can be traced back to the Han Dynasty (206 B.C.-220 A.D.). The extract of Polygonum multiflorum has been shown to prolong the life cycle of diploid cells/month to prolong the lifespan of Drosophila and old ticks, reduce the amount and activity of superoxide dismutase (SOD) and enhance the repair in aging organisms. The ability of power (Vag ,, w〇Hd Science and

Modernization of Traditional Chinese Medicine and Materia Medica (2005) 7(5):63-67^86) 〇 、 US 2002/146467 A1 及 US 7,083,81 1 B2揭示用於預防及 治療癡呆症之草本組合物,其包含何首烏及其他草藥。 CN 1 582975揭示一種用於治療腦血管疾病及老年癡呆症之 中、藥,其係由包括何首烏 '荷葉、地龍等五種中藥材經由 煎煮及在醇中萃取並乾燥製得。CN 1621〇78係關於一種中 藥組合物,其係由紅參(recj sage)、凍乾新鮮鹿算 (ginsenoside)、人參皂普(fieece fi〇wer root)、何首烏、黃 禮」seal wort)、山楂(haw)及大黃(rhubarb)製備以治療智力 衣退及療呆症。’ CN 1742968係關於一種治療血管性療呆症 之藥物’其係由中藥材何首烏、黃笑(astragalus root)、丹 參(salvia root)、當歸(ligusticum root)、石菖蒲(acorus root)、益智 Ί一(alphinia fruit)、銀杏葉總黃酮(ginkgo leaf total flavone)、地龍(earthworm)、水蛭(leech)及天麻 (gastrodia root)製備。 115989.doc 1377949 何首烏之一種主要組份為如圖所示之2,3,5,4'-四經基 二苯乙烯-2-0-β-ϋ-糖苷(TSG)。TSG可使用微波萃取方法 (參見 Wang, J.荨人,(2〇〇3) z/iongcaoyao 34 (4): 314· 317)逆’抓技術(參見 Zhang,T.等人 ’《/owrwa/ 〇/ • - Chromatography & Related Technologies (2QQ3) 26[9 & \Qy 1565-1577)、及使用液相萃取及層析之方法(參見Yan,χ, (1981) 8(2): 123 6&cn _ 1215728)萃取及分離。CN 1 159015C揭示利用逆相層析法 以氯仿後再以乙醇分離自何首烏中萃取之二苯乙烯糖苷化 合物。經在勤物實驗證明,二苯乙烯糖苷化合物能夠預防 由β-類澱粉蛋白及過氧化氫所引起之腦細胞損傷且增強患 有莨宕驗致癡呆症及Αβ癡呆症之小鼠的記憶能力。Zhang, L.等人(Clin. Pharm. J.,2005, 40 (10): 749-752)發現何首烏 中之2,3,5,4'-四羥基二苯乙烯_2_〇_p_d_糖苷(TSG)具有治療 大鼠膽鹼素性損傷之作用且在劑量低至3〇 mg/kg時,TSG Φ 可增強膽鹼乙醯基轉移酶(C h AT)活性及改良Μ -膽鹼素受體 -- 結合能力。CN 1 15901 5C^教示3,4,,5-三羥基·2-二苯乙烯 基-P-D-糖苷可用作治療阿茲海默氏症、血管性癡呆症及 - 認知功能障礙之藥劑。 • 文獻中亦指出綠茶能夠預防中風發生(參見Kakuda,Τ., Foods & Food Ingredients Journal of Japan (2001) 191: 51-5 5)。綠茶中之兒茶素被發現具有清除自由基作用而可 間接預防癡呆症。jg 2005-082495揭示綠茶中所含有之兒 茶素及丁胺酸(GABA)具有改善記憶及治療癡呆症及精神 115989.doc 49 病症之功效。 草之複雜性不僅存在於成份^上,亦存在於 早樂之間可能的相互作用上。因此,傳 不同於1古„ 千衆I作用完全 早"'目標及單1物關係之新型西藥的作用。 成’从鑑別單味十藥中之所有組份’故難以藉 法確定能在干方 3八中所各有之活性成份達到協同及/或 充效應。為研突Φ座+ a μ 丄a # 研九中樂之功效且由中樂製備治療劑,必須研 有效方法以分離'鑑別及純化草藥中之活性成份。 何首烏原料在使用之前必須加工以便自材料中 /導致腹4副作用之組份大黃素及大黃素^。在傳 方法中,將乾燥何首烏(〜以如⑽w ww/h//or_)浸 ,在於…'大旦汁中,並以蒸汽加熱,隨後乾燥以獲得稱為 "制首烏(Radix P〇lyg〇ni Multifl〇ri)”之產物。然而,在加 工期間’治療性活性成份會降解。因此,仍需要研發有效 方法以加工何首烏。此外’為改良何首烏萃取物之功效, 必須研發經濟且有效之方法以獲得包含最大量之則及兒 茶素及最低量之大黃素的產物。 【發明内容】 法 本發明之一個目的為提供一種製備何首烏萃取物之方 本發明之另—目的為提供一種何首烏萃取物。 本心月之另目的為提供一種組合物,其包含本發明之 何首烏萃取物。 本發明之又一目的為提供一種預防或治療個體之癡呆症 D5989.doc 1377949 (諸如老化相關之癡呆症、 或輕型η“知a 以海默氏症、金管性癡呆症 個俨其包含向需要該治療之 個體技斤本發明之組合物。 本發明之另一目的為提供—種本發 叮首烏卒取物的 ^ σ 頂防或冶療癡呆症(諸如老化相 關之癡呆症、阿兹海默氏症 S性癡呆症或輕型精神及 令力病症)之藥物。 在以下部分中詳細描述本發 “復轨 1不發明。本發明之其他特徵、目 的及優勢可易於見於本發明 中。 月之實施方式及中請專利範圍 【實施方式】 庫本Γ另外界^ ’否則本發明所用之科學及技術術語 應具有-般熟習此項技術者通常所理解之含義。該等術語Modernization of Traditional Chinese Medicine and Materia Medica (2005) 7(5): 63-67^86) 〇, US 2002/146467 A1 and US 7,083,81 1 B2 disclose a herbal composition for preventing and treating dementia, Contains Polygonum and other herbs. CN 1 582975 discloses a Chinese medicine for treating cerebrovascular diseases and Alzheimer's disease, which is prepared by extracting and drying five kinds of Chinese herbal medicines including Polygonum multiflorum, lotus leaf and earthworm. CN 1621〇78 relates to a traditional Chinese medicine composition which is composed of red ginseng, ginsenoside, fieece fi〇wer root, polygonum, and yellow seal. Haw and rhubarb are prepared to treat mental retraction and treatment. ' CN 1742968 relates to a drug for treating vascular spasm disease' which is composed of Chinese herbal medicines Heshouwu, Astragalus root, Salvia root, Lungusticum root, Acorus root, and puzzle. Alphinia fruit, ginkgo leaf total flavone, earthworm, leech and gastrodia root were prepared. 115989.doc 1377949 A major component of Polygonum multiflorum is 2,3,5,4'-tetramethylene stilbene-2-0-β-indole-glycoside (TSG) as shown. TSG can use the microwave extraction method (see Wang, J. 荨人, (2〇〇3) z/iongcaoyao 34 (4): 314· 317) to reverse the technique (see Zhang, T. et al. / /owrwa/ 〇/ • - Chromatography & Related Technologies (2QQ3) 26[9 & \Qy 1565-1577), and methods using liquid phase extraction and chromatography (see Yan, χ, (1981) 8(2): 123 6&amp ;cn _ 1215728) Extraction and separation. CN 1 159015 C discloses the use of reverse phase chromatography to extract stilbene glycoside compound extracted from Polygonum multiflorum with chloroform followed by ethanol. It has been proved in the physical experiments that the stilbene glycoside compound can prevent brain cell damage caused by β-amyloid protein and hydrogen peroxide and enhance the memory ability of mice suffering from dementia and Αβ dementia. Zhang, L. et al. (Clin. Pharm. J., 2005, 40 (10): 749-752) found 2,3,5,4'-tetrahydroxystilbene_2_〇_p_d_ in Polygonum multiflorum Glycoside (TSG) has the effect of treating choline-induced injury in rats. At doses as low as 3〇mg/kg, TSG Φ can enhance choline acetyltransferase (C h AT) activity and improve Μ-choline Receptor - binding ability. CN 1 15901 5C^ teaches that 3,4,5-trihydroxy-2-pyrphenyl-P-D-glycoside can be used as an agent for the treatment of Alzheimer's disease, vascular dementia and - cognitive dysfunction. • The literature also indicates that green tea can prevent strokes (see Kakuda, Τ., Foods & Food Ingredients Journal of Japan (2001) 191: 51-5 5). The catechins in green tea have been found to have a free radical scavenging effect and can prevent dementia indirectly. Jg 2005-082495 reveals that catechins and butylamine (GABA) contained in green tea have the effect of improving memory and treating dementia and psychosis. The complexity of grass exists not only in the composition, but also in the possible interactions between the early music. Therefore, it is different from the role of a new western medicine that is different from the ancient ones, and it is difficult to use the method to identify all the components of the single-medicine medicine. The synergistic and/or replenishing effect of each active ingredient in the dry side 3-8 is the effect of researching Φ座+ a μ 丄a # 研九中乐 and preparing therapeutic agents from Zhongle, it is necessary to study effective methods to separate 'Identify and purify the active ingredients in herbal medicines. Polygonum multiflorum raw materials must be processed before use to obtain emodin and emodin from the material/causing side effects. In the method of transmission, the Polygonum multiflorum will be dried (~ (10) w ww / h / / or_) dip, in ... 'large juice, and heated with steam, and then dried to obtain a product called "Radix P〇lyg〇ni Multifl〇ri". However, the therapeutically active ingredient degrades during processing. Therefore, there is still a need to develop effective methods for processing Polygonum multiflorum. In addition, in order to improve the efficacy of Polygonum multiflorum extract, it is necessary to develop an economical and effective method to obtain a product containing the maximum amount of catechin and the lowest amount of emodin. SUMMARY OF THE INVENTION One object of the present invention is to provide a method for preparing an extract of Polygonum multiflorum. Another object of the present invention is to provide an extract of Polygonum multiflorum. Another object of the present invention is to provide a composition comprising the Shouwu extract of the present invention. A further object of the present invention is to provide a dementia for preventing or treating an individual D5989.doc 1377949 (such as aging-related dementia, or light η "know a to Hermès, vascular dementia, its inclusion to the need The subject of the present invention is a composition of the present invention. Another object of the present invention is to provide a σ top prevention or treatment dementia (such as aging-related dementia, Az). A drug of the present invention is described in detail in the following section. "Re-track 1 is not invented. Other features, objects and advantages of the present invention can be readily seen in the present invention.实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 实施 이

之以及範奪應為清晰的;,然而,在任何潛在歧義之情況 下’本文所提供之定義優於任何辭典或外在定義。 :::外指[否則如本揭示内容所用之以下術語應理 解為具有以下含義。 示由超出自然老化所預期 能的進行性下降,諸如老 、每-管性癡呆症、輕型精 如本文所用之術語"癡呆症,,表 之腦損傷或疾病所引起之認知功 、化相關之癡呆症、阿兹海默氏症 神及智力病症及其類似病症。 如本文所用之術語"預防"係指遲 曰避延罹患疾病個體之症狀 發作gj咸少遠病出現。 病個體之症 如本文所用之術語"治療"表示緩解或改善感 115989.doc 1377949 狀。 * 如本文所用之術語"個體”表示動物、、 一較佳實施例中,術語••個體",、尤其哺乳動物。在 表不人類"。 文所用之術語"治療有效量"係 藥物組合使用以户瘩$ $ _ 、9早獨或與其他治療/ 量。 ’、力效之活性成份的 術語,,載劑”或"醫藥學上可接 項技術者所熟知之用以製備醫㈣係指一般熟習此 劑、接受劑或類似物。 …D物之稀釋劑、賦形 術何首烏草藥"係指植物何首 或整體、較佳係指植物的根。*、,,根、葉、莖及/ 術無水醇或藉由匈與水 液。根據本發明,醇具有含】至6個 =備之冷 碳©子曰s从 ’、子較佳含1至4個. 反原子且更佳含〗至3個碳 言,醇為甲醇,乙醇里石 炫基。舉例而 或乙醇。 合物。醇較佳為甲醇 除非本文另外需要,否則單數術語 語應包括單數。 #複數且複數術 製備方法 本發明之用於製備何首烏萃取物之方法包含以下步驟: )以醇洛液萃取何首烏草藥以獲得粗萃取物; )乂水稀釋步驟a)所獲得之粗萃取物以獲得經稀釋叙笠 取物; 卒 c)將步驟b)之經稀釋粗萃取物裝入樹脂管柱中; I15989.doc d) 自管柱t沖提何首烏萃取物;及 e) 收集沖提份以獲得提純之何首烏萃取物。 為之了法,步驟中所用之醇溶液中醇的濃度 1〇〇 ν/νβ/ 在—較佳實施例中,醇溶液為約10至 V V。之f醇溶液、較佳約2〇至9 最佳約2〇至5“/v%之甲醇溶液…4之甲和溶液、 醇溶液為約10至95 v/v%之乙蘇” X佳實施例中’ ,7 . /V/〇之乙醇溶液、較佳約10至30 v/v% 乙醇溶液、最佳約2〇 v/v%之乙醇溶液。 “根據本發明之方法,步驟狀粗萃取物可藉由任何習知 卒取法獲得’諸如藉由煎煮、浸潰、超音波處理、搜拌、 搜動或其組合。萃取時間為約小時、較佳約12至 24小時、最佳約17小時以上。萃取溫度為約5至95。〇、較 佳約呢邮、最佳在室溫下。萃取PH值為約25至91、 較:圭約2.5至5.3、最佳約5.3β在一較佳實施例中,何首烏 草藥係藉由冷萃取法(在室溫下超音波處理丨小時並攪拌Μ 小時)來萃取。 根據本發明之方法,在步驟b)中,以水稀釋粗萃取物以 便使經稀釋萃取物中醇之漠度為約wv%、較佳約2 至5 v/v%。在—較佳實施例中’經稀釋粗萃取物之醇濃度 為』2 v/v/〇 »在另一較佳實施例中,經稀釋粗萃取物之醇 》辰度為約5 v/v%。 根據本發明之方法,步驟c)中所用之樹脂係選自(但不限 於)大孔樹脂及凝膠樹脂。大孔樹脂較佳係選自diai〇n系 列、AmberHte系列及Dowex吸附劑,更佳mAi〇N系列。、 II59S9.doc 13 1377949 膠树月曰較佳係選自Sephadex系列、Toyopearl及 Sephacryl,更佳心邱以以系列。在一較佳實施例中,樹脂 為DIAION HP-20。在另一較佳實施例中,樹脂為Sephadex - LH-20。 .* 根據本發明之方法,在將經稀釋粗萃取物加至步騾c)之 吕柱引將樹脂以具有與步驟b)所獲得之經稀釋粗萃取物 相同之醇濃度的沖洗液沖洗。 痛· 根據本發明之方法,在沖提步驟d)之前,將管柱以具有 v驟b)所獲得之經稀釋粗萃取物相同之醇濃度的沖洗液 沖洗。 根據本發明之方法,在步驟d)中,為獲得何首烏萃取 物,將管柱以約1 〇至丨〇〇 v/v%、較佳約3〇至7〇%且更佳約 A之醇浴液沖提’並隨後以約7〇至1〇〇 v/v%之丙酮 溶液沖提《醇溶液可為具有遞增醇濃度之一系列醇溶液。 在較佳實施例中,將管柱用50 v/v%之甲醇溶液,隨後 • ι〇00/°之甲醇及最終1〇〇〇/。之丙酮沖提。在另一較佳實施例 -- 中,將管柱以50 v/v%之乙醇溶液,隨後95 v/v%之乙醇溶 液及最終100%丙酮沖提。在又一較佳實施例中,將管柱 . 用35 v/v%之乙醇溶液,隨後50 v/v%之乙醇溶液,隨後75 - v/v%之乙醇溶液,隨後95 Wv。/。之乙醇溶液及最終7〇 v/v% 之丙酮沖提。 本發明提供一種製備何首烏萃取物之有用方法。藉由本 發明之方法獲得之何首烏萃取物與傳統加工之何首烏萃取 物相比含有較多的2,3,5,4,-四羥基二苯乙烯-2-〇-β_〇_糖普 115989.doc 14 1377949 (TSG)及兒余素,及較少的大黃素(emd)及大黃素8-〇_卜 D-糖苦(EMDG)。冑由本發明之方法製備的何首烏萃取物 較佳者,要含有TSG及兒茶素。藉由本發明之方法裳備的 何首烏萃取物更佳者含有大於約65 之KG、大於約$ w/w。/。之兒命素,小於約〇 5 w/w%之emd及小於约〇 2And the rules should be clear; however, in any potential ambiguity, the definitions provided herein are superior to any dictionary or extrinsic definition. ::: External reference [Otherwise the following terms as used in this disclosure should be understood to have the following meanings. Shows progressive decline beyond the expected performance of natural aging, such as old, per-tube dementia, light essence as used herein, the term "dementia," the brain damage or disease caused by cognitive work, related Dementia, Alzheimer's disease and intellectual disorders and the like. The term "prevention" as used herein refers to the symptoms of an individual who has been delayed from suffering from a disease. Symptoms of a diseased individual As used herein, the term "treatment" indicates a relief or improvement of feeling 115989.doc 1377949. * The term "individual" as used herein denotes an animal, in a preferred embodiment, the term •• individual", especially a mammal. In the expression of human ". The term "therape effective amount" The combination of drugs used in households is $ _ _, 9 early alone or with other treatments/quantity. ', the terminology of active ingredients, carrier, or " pharmaceutically acceptable to those skilled in the art For the preparation of a medical (4) means that the agent, the recipient or the like is generally used. ...D thinner of the substance, the shape of the plant, the root of the plant, and the whole plant, preferably refers to the root of the plant. *,,, Roots, leaves, stems and / or anhydrous alcohol or by Hungarian and water. According to the present invention, the alcohol has a cold carbon content of from 至 to 6 = 从 s from ', preferably from 1 to 4. The anti-atomic and more preferably 〗 〖to 3 carbon, the alcohol is methanol, ethanol Li Shi Xuanji. For example or ethanol. Compound. The alcohol is preferably methanol. Unless otherwise required herein, the singular terms shall include the singular. The method for preparing the extract of Polygonum multiflorum of the present invention comprises the following steps:) extracting the extract of Polygonum multiflorum with alcohol solution to obtain a crude extract; and diluting the crude extract obtained by step a) with water Obtaining the diluted extract; step c) loading the diluted crude extract of step b) into the resin column; I15989.doc d) extracting the extract of Polygonum multiflorum from the column t; and e) collecting the extract Obtained purified Polygonum multiflorum extract. For this reason, the concentration of the alcohol in the alcohol solution used in the step is 1 〇〇 ν / νβ / In the preferred embodiment, the alcohol solution is about 10 to V V . The alcohol solution, preferably about 2 to 9 is preferably about 2 to 5" / v% of the methanol solution ... 4 of the solution A, the solution of the alcohol is about 10 to 95 v / v% of the Ethylene" X In the examples, the ethanol solution of ',7. /V/〇, preferably about 10 to 30 v/v% ethanol solution, preferably about 2 〇v/v% ethanol solution. "According to the method of the present invention, the step-like crude extract can be obtained by any conventional stroke method, such as by boiling, dipping, ultrasonic treatment, searching, searching, or a combination thereof. The extraction time is about hours, Preferably, it is about 12 to 24 hours, preferably about 17 hours or more. The extraction temperature is about 5 to 95. 〇, preferably about, preferably at room temperature. The extraction pH is about 25 to 91, compared with: About 2.5 to 5.3, preferably about 5.3 β In a preferred embodiment, the Polygonum multiflorum herb is extracted by cold extraction (ultrasonic treatment at room temperature for 丨 hours and stirring for Μ hours). According to the method of the present invention, In step b), the crude extract is diluted with water such that the alcohol in the diluted extract has an indifference of about wv%, preferably about 2 to 5 v/v%. In the preferred embodiment, the mixture is diluted. The alcohol concentration of the extract is "2 v/v/〇». In another preferred embodiment, the alcohol of the diluted crude extract has an elongation of about 5 v/v%. According to the method of the present invention, step c) The resin used in the selection is selected from, but not limited to, macroporous resins and gel resins. The macroporous resin is preferably selected from the diii〇n series and the AmberHte series. Dowex sorbent, better mAi 〇 N series., II59S9.doc 13 1377949 The gum tree is preferably selected from the group consisting of Sephadex series, Toyopearl and Sephacryl, and more preferably in series. In a preferred embodiment, the resin DIAION HP-20. In another preferred embodiment, the resin is Sephadex-LH-20. * According to the method of the present invention, the diluted crude extract is added to the step c) Rinse with a rinse solution having the same alcohol concentration as the diluted crude extract obtained in step b). Pain according to the method of the invention, prior to the stripping step d), the column is obtained with v (b) Rinse the rinse solution with the same alcohol concentration as the diluted crude extract. According to the method of the present invention, in step d), in order to obtain the extract of Polygonum multiflorum, the column is about 1 〇 to 丨〇〇v/v%, Preferably, the alcohol solution is extracted from an alcohol bath of about 3 〇 to 7 〇 % and more preferably about A and then eluted with an acetone solution of about 7 〇 to 1 〇〇 v/v%. A series of alcohol solutions. In a preferred embodiment, the column is treated with a 50 v/v% methanol solution followed by • ι〇00/° And finally the acetone is extracted. In another preferred embodiment, the column is in a 50 v/v% ethanol solution, followed by a 95 v/v% ethanol solution and finally 100%. Acetone flushing. In a further preferred embodiment, the column is used. A 35 v/v% ethanol solution followed by a 50 v/v% ethanol solution followed by a 75-v/v% ethanol solution followed by 95 Wv. /. ethanol solution and finally 7 〇 v / v% of acetone. The present invention provides a useful method for preparing extract of Polygonum multiflorum. The extract of Polygonum multiflorum obtained by the method of the present invention contains more 2,3,5,4,-tetrahydroxystilbene-2-indole-β_〇_糖普115989 than the traditionally processed Polygonum multiflorum extract. Doc 14 1377949 (TSG) and a small amount of emodin, and less emodin (emd) and emodin 8-〇_b D-sugar (EMDG). The extract of Polygonum multiflorum prepared by the method of the present invention preferably contains TSG and catechin. Preferably, the Polygonum multiflorum extract, which is carried out by the method of the present invention, contains KG greater than about 65 and greater than about $w/w. /. Child's life, less than about 〇 5 w/w% of emd and less than about 〇 2

w/w%之EMDG。藉由本發明之方法μ的何首冑萃取物最 佳者含有約65至85 w/w%之TSG及約5至1() w/w%之兒茶. 素。 ’、 根據本發明之方法’何首烏萃取物中四羥基二苯乙烯之 回收率與何首烏粗萃取物中相比大於約卿、較佳大於約 9〇%、★更佳大於約95%且最佳大於約97%。何首烏萃取物 中兒茶素之回收率與何首烏粗萃取物中相比大於約鳩, 較佳大於約75%且更佳大於約8〇%。 /艮據本發明之方法’步驟e)中所獲得之經沖提萃取物可 ,由任何習知溶液濃縮法遭縮’諸如使用減壓旋轉式汽化 裔來濃縮。 組合物 本發明提供一種組合物 之何首烏萃取物。 其包3冶療有效劑量之本發明 本發明之組合物可藉由任何合適投藥途徑(諸如經口投 '、才又與個體。合適的調配物包括(但不限於)錢劑、口含 劑、硬膠囊或軟膠囊、水性懸浮液或油性懸浮液、乳液、 性㈣或顆粒劑。必要時,可將其滅菌 、諸如穩定劑、濕潤劑及其類似物之醫藥學上可接兵之 115989.doc 1377949 载劑混合。 本發明之la合物可藉由習知程序使用此項技術中熟知之 $知醫藥賦形劑來製得。因此,欲經口使用之組合物可含 有例如一或多種著色劑、甜味劑、調味劑及/或防腐劑。w/w% of EMDG. The extract of Hessian extract by the method of the present invention preferably contains about 65 to 85 w/w% of TSG and about 5 to 1 () w/w% of catechin. The recovery of tetrahydroxystilbene in the extract of Polygonum multiflorum according to the method of the present invention is greater than about qing, preferably greater than about 9%, more preferably greater than about 95%, and most preferably compared to crude extract of Polygonum multiflorum. More than about 97%. The recovery rate of catechin in the extract of Polygonum multiflorum is greater than about 鸠, preferably greater than about 75% and more preferably greater than about 8%, compared to the crude extract of Polygonum multiflorum. The extracted extract obtained in accordance with the method of the present invention, step e), can be condensed by any conventional solution concentration method, such as concentration using a reduced pressure rotary vaporization. Composition The present invention provides a composition of a Polygonum multiflorum extract. The composition of the present invention may be administered by any suitable route of administration (such as oral administration) to an individual. Suitable formulations include, but are not limited to, money, oral preparations. , hard or soft capsules, aqueous suspensions or oily suspensions, emulsions, sexual (four) or granules. If necessary, they can be sterilized, such as stabilizers, humectants and their analogues. .doc 1377949 Carrier Mixing. The la compounds of the present invention can be prepared by conventional procedures using known pharmaceutical excipients well known in the art. Thus, compositions for oral use may contain, for example, one or A variety of coloring agents, sweeteners, flavoring agents and/or preservatives.

在AD治療中,本發明之組合物可與其他現有抗癡呆症 藥劑,諸如膽鹼酯酶抑制劑(例如利憶靈(Reminyl)、憶思 能(Exelon)、愛憶欣(Aricept)&康格憶(c〇gnex)及美金剛胺 (memantine))組合使用 〇 效用 本發明之組合物可用於預防或治療癡呆症,諸如老化相 關之癡呆症、P可茲海默氏症、血管性癡呆症、輕型精神及 智力病症及其類似病症。In the treatment of AD, the compositions of the present invention may be compatible with other existing anti-dementia agents, such as cholinesterase inhibitors (e.g., Reminyl, Exelon, Aricept & Combination of c〇gnex and memantine in combination with the effect of the present invention for preventing or treating dementia, such as aging-related dementia, P-Kehmer's disease, vascular Dementia, mild mental and intellectual disorders and the like.

熟習此項技術者應不難選擇治療之合適途徑及劑量。根 據本發明,较佳途徑為經口投與。劑量將視病症之性質及 病狀、患者之年齡及健康狀況、投藥途徑及任何先前治療 而定。熟習此項技術者應已知劑量可視個體年齡、大小、 健康狀況及其他相關因素而變化。 在-較佳實施例中,本發明之何首烏萃取物之最佳劑量 為每公斤體重約1至約25毫克。 但不 提供以下實例以輔助熟習此項技術者實踐本發明 明,因為在不恃離本發 一般熟習此項技術者可 應將該等實例理解為過度限制本發 明之發現的精神或範嘴之情況下, 對本文所述實施例進行修改及變化。 實例 115989.doc 何首烏萃取物之製備 #將乾燥何首烏植物磨碎後,與高極性溶劑(例如水、甲 醇乙醇、異丙醇或其混合物)混合並浸泡24小時。用筛 2或I紙m合物以移除植物組織殘餘物’以獲得澄清 ^棕色溶液(何首烏粗萃取物)。 月 將大孔樹脂或凝膠樹脂填入分離管柱中。管柱可由玻 璃、不鑛鋼或高分子聚合物(如pp)製成。若使用大孔樹 脂,則藉由乾式填充法將樹脂填入管柱中。若使用凝膠樹 脂’則將樹脂浸泡於水中,再將膨脹之樹脂填入管柱中。 树月曰之重里為原始乾燥植物重量之1 〇倍以上。將填充後之 吕柱以100〇/〇之甲醇或95 v/v%之乙醇溶液沖洗以移除雜 質,再以2至5 Wv%之醇水溶液平衡。 將適S之何首烏粗萃取物以水稀釋至溶劑之濃度為約2 至5 v/v%。將經稀釋之溶液注入分離管柱中。在將所有經 稀釋之溶液裝入管柱中後,將管柱以5倍管柱體積之2至5 v/v%之醇溶液沖洗,並隨後以不同比率之溶劑水混合物依 -人冲提官柱。將沖提份分別以減壓旋轉式汽化器濃縮並凍 乾以獲得萃取物粉末。 何首烏萃取物之複合分析法 儀益及設備:HPLC系統(Shimadzu HPLC系統,包括 SCL-lOAvp 系統控制器、LC-i〇ATvp泵、FCV-1〇ALvp四通 閥、SIL-lOADvp自動取樣器、SPD_M1〇Avp二極體陣列偵 測器、Alltech 2000 ELSD Evaporetive光散射偵測器及 ERC-3415a脫氣器) 115989.doc 17 1377949 分析管柱:Cosmosil C1 8-5MS(4.6x250mm) 條件: 流動速率:1 .〇 ml/min 分析時間:60 min 樣品量:1 〇 μ 1 PDA條件:取樣週期:〇·64 sec ;波長範圍:190-370 nm ;通道 z 254 nmThose skilled in the art should be able to choose the appropriate route and dosage for treatment. According to the present invention, the preferred route is oral administration. The dosage will depend on the nature of the condition and the condition, the age and condition of the patient, the route of administration, and any prior treatment. Those skilled in the art will recognize that the dosage will vary depending on the age, size, health and other relevant factors of the individual. In a preferred embodiment, the optimal dose of the extract of Polygonum multiflorum of the present invention is from about 1 to about 25 mg per kilogram of body weight. The following examples are not provided to assist those skilled in the art to practice the invention, as those skilled in the art are not to be construed as limiting the scope of the invention. In this case, modifications and variations are made to the embodiments described herein. Example 115989.doc Preparation of Polygonum multiflorum extract #When the dried Polygonum multiflorum plant is ground, it is mixed with a highly polar solvent (such as water, methanolic ethanol, isopropanol or a mixture thereof) and soaked for 24 hours. The sieve 2 or I paper was used to remove the plant tissue residue' to obtain a clear & brown solution (Heshouwu crude extract). Month Fill a large pore resin or gel resin into the separation column. The tubular string can be made of glass, non-mineral steel or high molecular weight polymers such as pp. If a macroporous resin is used, the resin is filled into the column by dry filling. If gel resin is used, the resin is immersed in water and the expanded resin is filled into the column. The weight of the tree is more than 1〇 of the original dry plant weight. The filled ruthenium column was rinsed with 100 〇/〇 methanol or 95 v/v% ethanol solution to remove impurities, and then equilibrated with 2 to 5 Wv% aqueous alcohol solution. The crude Shouwu extract of S. sinensis is diluted with water to a concentration of about 2 to 5 v/v%. The diluted solution is injected into the separation column. After loading all of the diluted solution into the column, the column is rinsed with a 2 to 5 v/v% alcohol solution at 5 column volumes and then with a different ratio of solvent water mixture. Official column. The extracts were separately concentrated in a reduced pressure rotary evaporator and lyophilized to obtain an extract powder. Composite analysis of Polygonum multiflorum extracts and equipment: HPLC system (Shimadzu HPLC system, including SCL-lOAvp system controller, LC-i〇ATvp pump, FCV-1〇ALvp four-way valve, SIL-lOADvp autosampler, SPD_M1〇Avp diode array detector, Alltech 2000 ELSD Evaporetive light scattering detector and ERC-3415a degasser) 115989.doc 17 1377949 Analytical column: Cosmosil C1 8-5MS (4.6x250mm) Condition: Flow rate :1 .〇ml/min Analysis time: 60 min Sample size: 1 〇μ 1 PDA conditions: sampling period: 〇·64 sec; wavelength range: 190-370 nm; channel z 254 nm

ELSD條件:溫度i〇(TC ;氮氣流動速率:3 〇 ml/min 對照樣品:TSG、兒茶素、EMDG及大黃素 移動相:B=l〇〇% 乙腈;C=甲醇;D=l〇 mM NH4OAc, pH 3.05 時間(min) ; δ B(CAN) C(MeOH) D(10 mM NH4OAc,pH 3.05) 0 10 90 5 ~~ 0 10 90 _ 35 100 0 0 50 100 0 0 _ 53 " 0 10 90 60 0 10 90 一ELSD conditions: temperature i〇(TC; nitrogen flow rate: 3 〇ml/min Control sample: TSG, catechin, EMDG and emodin mobile phase: B=l〇〇% acetonitrile; C=methanol; D=l 〇mM NH4OAc, pH 3.05 time (min); δ B(CAN) C(MeOH) D(10 mM NH4OAc, pH 3.05) 0 10 90 5 ~~ 0 10 90 _ 35 100 0 0 50 100 0 0 _ 53 &quot ; 0 10 90 60 0 10 90 one

測試何首烏萃取物活性之方法 利用 Nabeshima,T.及 Nitta,A.之動物模型(Tohoku J. Exp. Med.’ 1994, 174(3):241-249)測試何首烏萃取物之活性。 使用由腦室注射類澱粉肽(Αβ40)誘發之阿茲海默氏症大 鼠評估何首烏萃取物對由類澱粉卜肽誘發之 智力及學習力失能的治療效果。此外,使用以活體外神經 細胞拮抗類澱粉Αβ神經毒之活性篩檢技術分析何首烏萃取 物中之純化物質的生物活性。 實例1萃取溫度及溶劑之影響 115989.doc •18· 1377949 將5 g何首烏(PM)粉末添加至約50 ml水中且在100°C水浴 中萃取1小時。將混合物在室溫下以8,000 rpm之速度離心 1 5分鐘,隨後以1號濾紙抽氣過濾。收集到34 ml濾液 (PMWH)。Method for testing the activity of extracts of Polygonum multiflorum The activity of extracts of Polygonum multiflorum was tested using an animal model of Nabeshima, T. and Nitta, A. (Tohoku J. Exp. Med.' 1994, 174(3): 241-249). Alzheimer's disease rats induced by intraventricular injection of amyloid (Αβ40) were used to evaluate the therapeutic effect of Polygonum multiflorum extract on intelligence and learning disability induced by amyloid peptides. Further, the biological activity of the purified substance in the extract of Polygonum multiflorum L. was analyzed using an active screening technique using an in vitro neuronal cell antagonistic amyloid 神经β neurotoxin. Example 1 Effect of extraction temperature and solvent 115989.doc • 18· 1377949 5 g of Polygonum (PM) powder was added to about 50 ml of water and extracted in a 100 ° C water bath for 1 hour. The mixture was centrifuged at 8,000 rpm for 1 5 minutes at room temperature, followed by suction filtration through a No. 1 filter paper. 34 ml of filtrate (PMWH) was collected.

將2.5 g何首烏劑粉末分別以4種不同溶劑,亦即二次蒸 餾水、20 v/v%之乙醇溶液、50 v/v%之乙醇溶液及95 v/v% 之乙醇溶液冷萃取(在室溫下超音波處理1小時再以45 rpm 之速度旋轉震盪1 6小時)。隨後,將混合物在室溫下以 3,000 rpm之速度離心1 5分鐘,再以1號濾紙抽氣過濾以收 集第一次萃取物(PMWL-1、PM20EL-1、PM50EL-1 及 PM95EL-1)。將剩餘藥渣藉由上所述之冷萃取步驟再萃取 並收集第二次萃取物(PMWL-2、PM20EL-2、PM50EL-2及 PM95EL-2)。分析每一萃取物之萃取產率並以HPLC分析萃 取物中之大黃素(EMD)、大黃素-8-0-β-ϋ-糖苷(EMDG)及 2,3,5,4'-四羥基二苯乙烯-2-0-β-ϋ-糖苷(TSG)之量。各萃取 方法及批次之萃取產率概述於表1中。 表1利用不同萃取法及多次萃取之萃取率 樣品 第一次萃取物 第二次萃取物 萃取方法 萃取物之量 (mg/ml) 萃取率 (%) 萃取物之量 (mg/ml) 萃取率 (%) PMWH(熱水萃取) 34 23.1 - - PMWL(室溫水萃取) 24.9 19.1 3.7 3.4 PM20EL(室溫20°/。之乙醇萃取) 30.3 23.1 5.5 5.1 PM50EL(室溫50°/。之乙醇萃取) 33.4 26.2 5.1 4.5 PMEL(室溫95%之乙醇萃取) 20.7 19.7 2.5 2.8 如表1所示,熱水萃取之萃取率與室溫水萃取之萃取率 相比高約20%。若以乙醇溶液作為萃取溶劑,則利用50% 115989.doc -19- 1377949 之乙醇溶液的方法具有最高之萃取率。總之,第一次萃取 之萃取率為約19至26%,而第二次萃取之萃取率僅為3至 5%。EMD、EMDG及TSG之量的分析結果概述於表2中。 表2不同萃取物中EMD、EMDG及TSG之量 成份之量(mg) PMWH PMWL PM20EL PM50EL PM95EL EMD 0.00 0.13 0.00 1.88 3.88 EMDG 1.34 0.00 0.00 0.00 8.72 TSG 20.40 28.78 32.61 56.28 40.082.5 g of Polygonum powder was extracted in four different solvents, namely, double distilled water, 20 v/v% ethanol solution, 50 v/v% ethanol solution and 95 v/v% ethanol solution (in the room). Under the temperature, the ultrasonic treatment was performed for 1 hour and then rotated at 45 rpm for 16 hours). Subsequently, the mixture was centrifuged at 3,000 rpm for 15 minutes at room temperature, and then filtered with a No. 1 filter paper to collect the first extract (PMWL-1, PM20EL-1, PM50EL-1, and PM95EL-1). . The remaining dregs were re-extracted by the cold extraction step described above and the second extracts (PMWL-2, PM20EL-2, PM50EL-2 and PM95EL-2) were collected. The extraction yield of each extract was analyzed and the emodin (EMD), emodin-8-0-β-ϋ-glycoside (EMDG) and 2,3,5,4'- in the extract were analyzed by HPLC. The amount of tetrahydroxystilbene-2-0-β-indole-glycoside (TSG). The extraction yields for each extraction method and batch are summarized in Table 1. Table 1 Extraction rate using different extraction methods and multiple extractions Samples First extraction Second extraction method Extraction amount (mg/ml) Extraction rate (%) The amount of extract (mg/ml) Extraction Rate (%) PMWH (hot water extraction) 34 23.1 - - PMWL (room temperature water extraction) 24.9 19.1 3.7 pm PM20EL (ethanol extraction at room temperature 20 ° /.) 30.3 23.1 5.5 5.1 PM50EL (room temperature 50 ° /. Ethanol extraction) 33.4 26.2 5.1 4.5 PMEL (95% ethanol extraction at room temperature) 20.7 19.7 2.5 2.8 As shown in Table 1, the extraction rate of hot water extraction is about 20% higher than the extraction rate of room temperature water extraction. If an ethanol solution is used as the extraction solvent, the method using 50% of the 115989.doc -19-1377949 ethanol solution has the highest extraction rate. In summary, the extraction rate for the first extraction is about 19 to 26%, while the extraction rate for the second extraction is only 3 to 5%. The analysis results of the amounts of EMD, EMDG and TSG are summarized in Table 2. Table 2 EMD, EMDG and TSG in different extracts Quantity of ingredients (mg) PMWH PMWL PM20EL PM50EL PM95EL EMD 0.00 0.13 0.00 1.88 3.88 EMDG 1.34 0.00 0.00 0.00 8.72 TSG 20.40 28.78 32.61 56.28 40.08

以室溫水萃取之萃取物中TSG之量與以熱水萃取之萃取 物中TSG之量相比高約40%。以室溫水萃取之萃取物含有 EMD,而以熱水萃取之萃取物含有EMDG。當以乙醇溶液 萃取時,以50%之乙醇溶液萃取之萃取物含有最大量之 TSG。然而,EMD及EMDG之量隨乙醇濃度增加而增加。 雖然以20%之乙醇溶液萃取之萃取物中TSG之含量不是最 高,但其不含有EMD或EMDG。因此,以TSG萃取率及萃 取物之品質來評估,在室溫下利用20%之乙醇溶液的萃取 法具有最大效益。The amount of TSG in the extract extracted with room temperature water was about 40% higher than the amount of TSG in the extract extracted with hot water. The extract extracted with room temperature water contains EMD, and the extract extracted with hot water contains EMDG. When extracted with an ethanol solution, the extract extracted with a 50% ethanol solution contains the maximum amount of TSG. However, the amount of EMD and EMDG increases as the concentration of ethanol increases. Although the TSG content of the extract extracted with a 20% ethanol solution is not the highest, it does not contain EMD or EMDG. Therefore, the extraction method using a 20% ethanol solution at room temperature has the greatest benefit as assessed by the TSG extraction rate and the quality of the extract.

實例2 萃取溶劑比率及pH值的影響 製備三種不同溶劑(10 v/v%、20 v/v%及3 0 v/v%之乙醇 溶液)。將2 g何首烏粉末添加至20 ml之各溶劑中,且每一 溶劑各製備三管混合物。將各溶劑之三管混和物各以 NaOH及HC1調整pH值至分別為2.5、5.3及9.1。隨後,將各 管超音波處理1小時且以45 rpm之速度旋轉混和16小時。 將每一樣品以3,000 rpm之速度離心15分鐘並收集上清液。 上清液之成份分析概述於表3中。 115989.doc -20- 1377949 表3利用不同溶劑及pH值萃取之何首烏(PM)萃取物中 EMD、EMDG 及 TSG 之量 pH值 2.5 5.3 9.1 溶劑(乙醇 濃度) 10% 20% 30% 10% 乂 20% 30% 10% 20% 30% 成份之量< :mg/g PM 粉末) EMD 0.14 0.18 0.36 0.19 0.26 0.38 1.22 1.61 2.03 EMDG 0.98 1.05 1.20 ;0.00 0.00 0.00 0.60 1.04 1.60 TSG 22.12 22.01 25.20 1 25.75 25.35 27.24 0.00 0.00 2.43Example 2 Effect of extraction solvent ratio and pH Three different solvents (10 v/v%, 20 v/v%, and 30 v/v% ethanol solution) were prepared. 2 g of Polygonum multiflorum powder was added to 20 ml of each solvent, and a three-tube mixture was prepared for each solvent. The three tube mixtures of the respective solvents were adjusted to pH values of 2.5, 5.3 and 9.1 with NaOH and HCl, respectively. Subsequently, each tube was ultrasonicated for 1 hour and rotated and mixed at a speed of 45 rpm for 16 hours. Each sample was centrifuged at 3,000 rpm for 15 minutes and the supernatant was collected. The composition analysis of the supernatant is summarized in Table 3. 115989.doc -20- 1377949 Table 3 EMD, EMDG and TSG in extracts of Polygonum multiflorum (PM) extracted with different solvents and pH pH 2.5 5.3 9.1 Solvent (ethanol concentration) 10% 20% 30% 10% 乂20% 30% 10% 20% 30% Amount of ingredients < :mg/g PM powder) EMD 0.14 0.18 0.36 0.19 0.26 0.38 1.22 1.61 2.03 EMDG 0.98 1.05 1.20 ;0.00 0.00 0.00 0.60 1.04 1.60 TSG 22.12 22.01 25.20 1 25.75 25.35 27.24 0.00 0.00 2.43

如表3所示,在三種pH值下EMD之量隨乙醇濃度之升高 而增加(10%<20%<30%)。以30%之乙醇溶液萃取之EMD的 量約為以20%之乙醇溶液萃取之EMD的量之兩倍。在pH值 9.1的條件下,以三種溶劑萃取何首烏幾乎不會萃取出 TSG。在pH值為5.3及2.5下,當乙醇濃度升高時所萃取之 丁80的量類似且略有增加(10%$20%<3 0%)。在卩1^值5.3的 條件下,三種溶劑皆不能萃取出EMDG ;然而在μΗ值2.5及 9.1的條件下,可萃取出一些EMDG,且其量隨乙醇濃度之 升高而增加(10%<20%<30°/〇)。As shown in Table 3, the amount of EMD at three pH values increased with increasing ethanol concentration (10% < 20% < 30%). The amount of EMD extracted with a 30% ethanol solution was about twice the amount of EMD extracted with a 20% ethanol solution. At a pH of 9.1, extraction of Polygonum multiflorum with three solvents will hardly extract TSG. At pH 5.3 and 2.5, the amount of D8 extracted as the ethanol concentration increased was similar and slightly increased (10%$20% < 30%). Under the condition of 5.31^ value 5.3, EMDG could not be extracted by the three solvents; however, under the condition of μΗ2.5 and 9.1, some EMDG could be extracted, and the amount increased with the increase of ethanol concentration (10% <;20%<30°/〇).

實例2之結果顯示萃取何首烏之最佳條件為在pH值5.3下 利用1 0至20°/。之乙醇溶液萃取。在此條件下,可有效萃取 TSG,且萃取出最少量之EMD及EMDG。當萃取pH值降低 至2.5時,TSG之量減少約10%,EMD之量減少約30%,而 EMDG之量增加。 實例3 利用大孔樹脂萃取何首烏之活性成份 將1 00 g何首烏粉末以1公升甲醇冷萃取(在室溫下超音波 處理1小時再攪拌16小時)。將所萃取之溶液以1號濾紙抽 氣過濾並收集900 ml濾液(PM901)。 I15989.doc 1377949The results of Example 2 show that the optimum conditions for extracting Polygonum multiflorum are 10 to 20 °/ at pH 5.3. The ethanol solution is extracted. Under these conditions, the TSG can be effectively extracted and the minimum amount of EMD and EMDG extracted. When the extraction pH is lowered to 2.5, the amount of TSG is reduced by about 10%, the amount of EMD is reduced by about 30%, and the amount of EMDG is increased. Example 3 Extraction of active ingredients of Polygonum multiflorum using macroporous resin 1000 g of Polygonum multiflorum powder was cold extracted with 1 liter of methanol (ultrasonic treatment at room temperature for 1 hour and then stirred for 16 hours). The extracted solution was suction-filtered on a No. 1 filter paper and 900 ml of a filtrate (PM901) was collected. I15989.doc 1377949

將 100 g DIAION HP-20樹脂(Mitsubishi Chemicals)填入 層析管柱(ID=40 mm ; L=200 mm)中,並將管柱以1公升曱 醇再循環1小時。隨後將管柱以2公升5 v/v%之甲醇溶液沖 洗。將400 ml PM901以純水稀釋至最终體積為8公升,使 甲醇之最终濃度為5%。將經稀釋溶液以15 ml/min之流動 速率加入DIAION管柱中並收集未吸附液。將管柱以1公升 5 v/v%之曱醇溶液沖洗並使沖洗液與未吸附液合併,隨後 以減壓旋轉式汽化器將合併之液體濃縮至50 ml (PM902)。100 g of DIAION HP-20 resin (Mitsubishi Chemicals) was packed into a chromatography column (ID = 40 mm; L = 200 mm), and the column was recirculated with 1 liter of decyl alcohol for 1 hour. The column was then rinsed with 2 liters of 5 v/v% methanol solution. 400 ml of PM901 was diluted with pure water to a final volume of 8 liters to a final concentration of 5% methanol. The diluted solution was added to the DIAION column at a flow rate of 15 ml/min and the unadsorbed liquid was collected. The column was rinsed with 1 liter of 5 v/v% sterol solution and the rinse was combined with the non-adsorbed liquid, and then the combined liquid was concentrated to 50 ml (PM902) with a reduced pressure rotary evaporator.

隨後將管柱以1.5公升50 v/v%之曱醇溶液沖提。收集經 沖提液體並將其以減壓旋轉式汽化器濃縮至200 ml(PM903)。將管柱以1.5公升100%之曱醇進一步沖提。收 集經沖提液體並將其以減壓旋轉式汽化器濃縮至200 ml(PM904)。最終,將管柱以1公升100%之丙酮沖提。收 集經沖提液體並將其以減壓旋轉式汽化器濃縮至50 ml(PM905)。樣品(管柱分離前或管柱分離後所收集者)中 TSG及兒茶素之量及回收率顯示於表4中。 表4 PM901至PM905中TSG及兒茶素之量及回收率 樣品 兒茶素之 總量(mg) 兒茶素之 回收率(%) 樣品中兒茶 素之百分比 (%) TSG之 總量(g) T^G之回 收率(%) 樣品中TSG 之百分比 (%) PM901 10.8 100 0.13 1.7 100 21.2 PM902 1.6 14.8 0 0 0 0 PM903 8.6 79.6 0.31 1.5 88.2 54.3 PM904 0 0 0 0.1 5.8 14.6 PM905 0 0 0 0 0 0 如表4所示,甲醇萃取之樣品(PM901)中TSG及兒茶素之 百分比分別為21.2%及0.13%。可將所萃取之樣品PM901藉 115989.doc -22- 1377949 由管柱分離以50°/。之甲醇溶液進一步提純以得到2.8 g PM903。PM903中TSG之百分比為54.3%,其為最初百分比 之2.6倍且PM903中兒茶素之百分比為0.31%,其為最初百 分比之3倍。TSG及兒茶素之回收率分別為88.2%及 79.6%。 實例4 利用大孔樹脂萃取何首烏活性成份The column was then flushed with 1.5 liters of 50 v/v% sterol solution. The extracted liquid was collected and concentrated to 200 ml (PM903) in a reduced pressure rotary evaporator. The column was further stripped with 1.5 liters of 100% sterol. The extracted liquid was collected and concentrated to 200 ml (PM904) in a reduced pressure rotary evaporator. Finally, the column was flushed with 1 liter of 100% acetone. The extracted liquid was collected and concentrated to 50 ml (PM905) in a reduced pressure rotary evaporator. The amount and recovery of TSG and catechin in the sample (before the column separation or after the column separation) are shown in Table 4. Table 4 TSG and catechin amount and recovery rate in PM901 to PM905 Total amount of sample catechin (mg) Recovery rate of catechin (%) Percentage of catechin in sample (%) Total amount of TSG ( g) Recovery of T^G (%) Percentage of TSG in the sample (%) PM901 10.8 100 0.13 1.7 100 21.2 PM902 1.6 14.8 0 0 0 0 PM903 8.6 79.6 0.31 1.5 88.2 54.3 PM904 0 0 0 0.1 5.8 14.6 PM905 0 0 0 0 0 0 As shown in Table 4, the percentages of TSG and catechin in the methanol-extracted sample (PM901) were 21.2% and 0.13%, respectively. The extracted sample PM901 can be separated from the column by 50°/ by 115989.doc -22- 1377949. The methanol solution was further purified to give 2.8 g of PM903. The percentage of TSG in PM903 was 54.3%, which was 2.6 times the initial percentage and the percentage of catechin in PM903 was 0.31%, which was 3 times the original percentage. The recovery rates of TSG and catechin were 88.2% and 79.6%, respectively. Example 4 Extraction of active ingredients of Polygonum multiflorum using macroporous resin

將180.10 g何首烏粉末以1.8公升20 v/v%之乙醇溶液冷 萃取(在室溫下超音波處理1小時再攪拌1 6小時)。將萃取之 溶液在25°C下以8,000 rpm之速度離心15分鐘,並隨後以1 號濾紙抽氣過濾。收集1,840 ml濾液(PM20EL)並量測固體 物質之量。180.10 g of Polygonum multiflorum powder was cold extracted with 1.8 liters of 20 v/v% ethanol solution (ultrasonic treatment at room temperature for 1 hour and then stirred for 16 hours). The extracted solution was centrifuged at 8,000 rpm for 15 minutes at 25 ° C, and then suction filtered with a No. 1 filter paper. 1,840 ml of filtrate (PM20EL) was collected and the amount of solid matter was measured.

將300.08 g DIAION HP-20樹脂填入層析管柱(ID=80 mm; L = 295 mm)中,並以2.0公升95 v/v 0/〇之乙醇溶液將管 柱再循環1.5小時。隨後將管柱用4.38公升2 v/v%之乙醇溶 液沖洗。將1,533 ml PM20EL以純水稀釋至15,330 m卜使 乙醇之最終濃度為2%。將經稀釋溶液以15 ml/min之流動 速率加入DIAION管柱中並收集未吸附液。將管柱以3.84公 升2 v/v%之曱醇溶液沖洗且使沖洗液與未吸附液合併,合 併之液體總體積為16,840 ml(PM801)。 隨後將管柱以6.5公升50 v/v%之乙醇溶液沖提。收集最 初200 ml黃橙色之沖提液體並將所收集之液體與剩餘萃取 液體合併為PM802。樣品(管柱分離前或管柱分離後所收集 者)中TSG及兒茶素之量及回收率顯示於表5中。 表5 PM20EL、PM801及PM802中TSG及兒茶素之量及回 115989.doc -23- 1377949 收率 樣品 兒茶素之 總量(mg) 兒茶素之回 收率(%) 樣品中兒茶素 之百分比(%) TSG之總 量(g) TSG之回收 率(%) 樣品中TSG 之百分比(%) PM20EL 41.4 100.0 0.11 5.2 100.0 14.3 PM801 0.6 1.5 0.02 0.0 0.0 0.0 PM802 28.9 69.9 0.32 4.8 91.2 52.3300.08 g of DIAION HP-20 resin was packed into a chromatography column (ID = 80 mm; L = 295 mm), and the column was recirculated for 1.5 hours with a 2.0 liter 95 v/v 0/〇 ethanol solution. The column was then rinsed with 4.38 liters of 2 v/v% ethanol solution. Dilute 1,533 ml of PM20EL to 15,330 m in pure water so that the final concentration of ethanol is 2%. The diluted solution was added to the DIAION column at a flow rate of 15 ml/min and the unadsorbed liquid was collected. The column was rinsed with a 3.84 liter 2 v/v% sterol solution and the rinse was combined with the non-adsorbed solution to a total volume of 16,840 ml (PM801). The column was then flushed with 6.5 liters of 50 v/v% ethanol solution. The initial 200 ml yellow-orange extract liquid was collected and the collected liquid was combined with the remaining extraction liquid into PM802. The amount and recovery of TSG and catechin in the sample (collected before or after separation of the column) are shown in Table 5. Table 5 The amount of TSG and catechins in PM20EL, PM801 and PM802 and back 115989.doc -23- 1377949 Yield The total amount of sample catechins (mg) The recovery rate of catechins (%) The catechins in the sample Percentage (%) Total amount of TSG (g) Recovery rate of TSG (%) Percentage of TSG in the sample (%) PM20EL 41.4 100.0 0.11 5.2 100.0 14.3 PM801 0.6 1.5 0.02 0.0 0.0 0.0 PM802 28.9 69.9 0.32 4.8 91.2 52.3

如表5所示,50%乙醇溶液萃取樣品(PM20EL)中TSG及 兒茶素之百分比分別為1 4.3%及0.11 %。將所萃取之樣品 PM20EL以50%之曱醇沖提溶液使用管柱分離進一步提純 以得到9.1 g PM802。PM802中TSG之百分比為52.30/。,其 為最初百分比之3.6倍’且PM802中兒茶素之百分比為 0.32%,其為最初百分比之3倍。TSG及兒茶素之回收率分 別為91.2%及69.9%。根據實例4之結果,本發明之製備方 法可有效分離TSG及兒茶素,並控制損失率低至 8.8°/〇(TSG)及 3 0.1°/。(兒茶素)。 實例5利用凝膠樹脂萃取何首烏活性成份As shown in Table 5, the percentages of TSG and catechin in the 50% ethanol solution sample (PM20EL) were 14.3% and 0.11%, respectively. The extracted sample PM20EL was further purified by column separation using a 50% decyl alcohol extracting solution to obtain 9.1 g of PM802. The percentage of TSG in PM802 is 52.30/. , which is 3.6 times the initial percentage' and the percentage of catechins in PM802 is 0.32%, which is three times the initial percentage. The recovery rates of TSG and catechin were 91.2% and 69.9%, respectively. According to the results of Example 4, the preparation method of the present invention can effectively separate TSG and catechin, and control the loss rate as low as 8.8 ° / 〇 (TSG) and 3 0.1 ° /. (catechin). Example 5 extraction of active ingredients of Polygonum multiflorum using gel resin

將30 g Sephadex LH-20樹脂(Pharmacia)填入層析管柱 中,並以500 ml 95 v/v%之乙醇溶液以20 ml/min之流動速 率再循環2小時。隨後將管柱以500 ml 2 v/v%之乙醇溶液 沖洗。將由實例4獲得之132 ml PM20EL-1以M.Q.水稀釋至 最終體積為1000 ml。將經稀釋溶液裝入LH-20管柱中,並 收集未吸附淺棕色混濁液體。隨後將管柱用500 ml 2 v/v% 之乙醇溶液再沖洗。使最初15 0 m 1沖洗液與未吸附液合 併,並以減壓旋轉式汽化器將合併之液體濃縮至25 ml(PM211)。收集剩餘345 ml淺黃色澄清沖洗液,並以減 壓旋轉式汽化器將其濃縮至10 ml(PM212)。將PM211及 115989.doc •24- 1377949 PM212 合併為 PMLH201。 先將管柱以250 ml 35 v/v%之乙醇溶液沖提,收集244 ml沖提液體(最初80 ml為淺黃色,而剩餘164 ml為淺黃棕 色),並以減壓旋轉式汽化器將其濃縮至25 ml (PMLH202c) °30 g of Sephadex LH-20 resin (Pharmacia) was packed into a chromatography column and recycled in a 500 ml 95 v/v% ethanol solution at a flow rate of 20 ml/min for 2 hours. The column was then rinsed with 500 ml 2 v/v% ethanol solution. 132 ml of PM20EL-1 obtained in Example 4 was diluted with M.Q. water to a final volume of 1000 ml. The diluted solution was placed in an LH-20 column and the unadsorbed light brown turbid liquid was collected. The column was then rinsed again with 500 ml 2 v/v% ethanol solution. The first 150 m 1 rinse was combined with the non-adsorbed liquid, and the combined liquid was concentrated to 25 ml (PM211) with a reduced pressure rotary evaporator. The remaining 345 ml of light yellow clarified rinse was collected and concentrated to 10 ml (PM212) using a reduced pressure rotary evaporator. Combine PM211 and 115989.doc •24- 1377949 PM212 into PMLH201. The column was first flushed with 250 ml of 35 v/v% ethanol solution, and 244 ml of the extracted liquid was collected (the first 80 ml was light yellow and the remaining 164 ml was light yellowish brown) and was compressed in a reduced pressure vaporizer. It is concentrated to 25 ml (PMLH202c) °

隨後將管柱以250 ml 50 v/v%之乙醇溶液沖提,收集244 ml沖提液體(最初60 ml為淺黃棕色,而剩餘184 ml為黃棕 色),並以減壓旋轉式汽化器將其濃縮至25 ml (PMLH203C) ° 再將管柱以25 0 ml 75 v/v。/。之乙醇溶液沖提,收集242 ml沖提液體(最初70 ml為淺黃棕色,其次56 ml為黃棕色, 而剩餘11 6 ml為淺橘黃色)’並以減壓旋轉式汽化器將其濃 縮至 25 ml(PMLH204c)。The column was then flushed with 250 ml of 50 v/v% ethanol solution and 244 ml of the extracted liquid was collected (the first 60 ml was light yellowish brown and the remaining 184 ml was yellowish brown) and was compressed in a reduced pressure vaporizer. It was concentrated to 25 ml (PMLH203C) ° and the column was then 25 0 ml 75 v/v. /. The ethanol solution was extracted and 242 ml of the extracted liquid was collected (the first 70 ml was light yellowish brown, followed by 56 ml of yellowish brown, and the remaining 11 6 ml was light orange) and concentrated to a reduced pressure rotary evaporator. 25 ml (PMLH204c).

接著將管柱以250 ml 95 v/v%之乙醇溶液沖提,收集246 ml沖提液體(最初70 ml為淺橘黃色,而剩餘176 ml為無 色),並以減壓旋轉式汽化器將其濃縮至25 ml (PMLH205c) ° 最後將管枉以250 ml 70 v/v%之丙酮溶液沖提,收集246 沖提液體,並以減壓旋轉式汽化器將其漢縮至25 ml(PMLH206c)»分析每一濃縮樣品(沖提份)中固體物質之 量及活性成份之比率,結果顯示於表6中。 表6每一沖提份中TSG、EMD、EMDG及兒茶素之量及回 收率 115989.doc 25- 1377949 沖提份 溶劑 固體物TSG之TSG 質之量 量 之回 (mg/ml)(mg/ml)收率 (%) TSG EMD EMD與 與固之量固體物 體物(μβ/πιΐ)質之比 質之 率(%) 比率 (%) EMDG 之量 (Mg/ml) EMDG 與固體 物質之 比率(°/〇) 兒茶素兒茶素 之量與固體 (mg/ml)物質之 比率(%) PM20EL-1 20% EtOH 26.4 2.8 100 10.6 8.0 0.03 0 0.00 0 0.00 PMLH201 20% EtOH(未 結合) 84.0 0.6 4.7 0.7 <3.5 <0.004 <5 <0.01 0.7 0.83 PMLH202C 35% EtOH 8.5 6.9 53.6 81.2 <3.5 <0.041 7 0.08 0.7 8.24 PMLH203C 50% EtOH 7.1 5.6 43.5 78.9 21.9 0.31 <5 <0.07 <0.5 <7.04 PMLH204C 75% EtOH 3.2 0 0 0 4.0 0.13 0 0.00 0 0.00 PMLH205C 95% EtOH 1.2 0 0 0 0 0.00 0 0.00 0 0.00 PMLH206C 70%丙酮 10.8 0 0 0 0 0.00 0 0.00 0 0.00The column was then stripped with 250 ml of 95 v/v% ethanol solution and 246 ml of the rinse liquid was collected (the first 70 ml was light orange and the remaining 176 ml was colorless) and was compressed with a reduced pressure rotary evaporator. Concentrate to 25 ml (PMLH205c) ° Finally, pipette was flushed with 250 ml 70 v/v% acetone solution, 246 extracts were collected and compressed to 25 ml (PMLH206c) with a reduced pressure rotary evaporator. The ratio of the amount of solid matter to the active ingredient in each concentrated sample (flush) was analyzed and the results are shown in Table 6. Table 6 The amount and recovery of TSG, EMD, EMDG and catechin in each of the extracts 115989.doc 25- 1377949 The amount of the TSG mass of the solvent solid TSG (mg/ml) (mg /ml) Yield (%) TSG EMD EMD Equivalent to the solid matter (μβ/πιΐ) mass ratio (%) Ratio (%) EMDG amount (Mg/ml) EMDG and solid matter Ratio (°/〇) The ratio of the amount of catechin catechin to the solid (mg/ml) substance (%) PM20EL-1 20% EtOH 26.4 2.8 100 10.6 8.0 0.03 0 0.00 0 0.00 PMLH201 20% EtOH (unbound 84.0 0.6 4.7 0.7 <3.5 <0.004 <5 <0.01 0.7 0.83 PMLH202C 35% EtOH 8.5 6.9 53.6 81.2 <3.5 <0.041 7 0.08 0.7 8.24 PMLH203C 50% EtOH 7.1 5.6 43.5 78.9 21.9 0.31 <5 <0.07 <0.5 <7.04 PMLH204C 75% EtOH 3.2 0 0 0 4.0 0.13 0 0.00 0 0.00 PMLH205C 95% EtOH 1.2 0 0 0 0 0.00 0 0.00 0 0.00 PMLH206C 70% Acetone 10.8 0 0 0 0 0.00 0 0.00 0 0.00

如表6所示,多數TSG可藉由35至50%之乙醇溶液沖提, 且總回收率為97%以上。兒茶素及EMDG可於同一沖提份 中沖提,但大多數EMD係藉由50%之乙醇溶液沖提。實例 5之結果表示當以LH-樹脂作為分離材料時,最佳沖提溶液 為35至40 v/v%之乙醇溶液。 實例6 藉由使用Αβ注射劑誘發之阿茲海默氏大鼠模型 ΡΜ903的認知行為評估 在大鼠中誘發神經退化 Αβ 1-40注入大鼠模型為一種快速篩檢用於治療阿茲海 默氏症藥物的動物模型。藉由將Αβ 1-40緩慢注入大鼠之 第三側腦室中而誘發大鼠模型之神經退化,以藉由腦脊髓 液(CSF)系統損傷海馬區而造成認知行為障礙。 為製備阿茲海默氏症大鼠,將Αβ 1-40溶液注入Alzet滲 透泵(Alzet 1002 ; DURECT Co.,USA)中且將腦灌注套組 之PE管與泵連接。將大鼠以戊巴比妥’納(sodium pentobarbital)(45 mg/kg)麻醉,並置放於立體定位儀 -26- 115989.doc 1377949As shown in Table 6, most TSGs can be extracted with 35 to 50% ethanol solution, and the total recovery is over 97%. The catechins and EMDG can be extracted from the same portion, but most of the EMD is eluted with a 50% ethanol solution. The results of Example 5 indicate that when LH-resin was used as the separation material, the optimum elution solution was a 35 to 40 v/v% ethanol solution. Example 6 Induction of neurodegeneration in rats by the cognitive behavioral assessment of Alzheimer's rat model ΡΜ903 induced by Αβ injection Αβ 1-40 was injected into the rat model as a rapid screening for the treatment of Alzheimer's Animal model of the disease drug. The neurodegeneration of the rat model was induced by slowly injecting Αβ 1-40 into the third lateral ventricle of the rat to cause cognitive behavioral disorder by injuring the hippocampus region by the cerebrospinal fluid (CSF) system. To prepare Alzheimer's disease rats, a Αβ 1-40 solution was injected into an Alzet osmotic pump (Alzet 1002; DURECT Co., USA) and the PE tube of the cerebral perfusion set was connected to a pump. The rats were anesthetized with sodium pentobarbital (45 mg/kg) and placed on a stereotaxic instrument -26- 115989.doc 1377949

(31'0£1/1'以0,1;3八;1^〇(161 51650)上以定位側腦室。將腦 灌注套組插入大鼠之第三側腦室十,並將Alzet滲透泵植入 大鼠頸後之皮下區域。將手術區域縫合且將大鼠置放於籠 中。在對照組(Sham)中,將Alzet滲透泵中之Αβ 1-40溶液 以35%乙腈/0.1%三氟乙酸替代。植入之後8至9天,對大鼠 進行被動迴避測試。植入之後1〇至15天,使用Morris水迷 宮(water maze)評估大鼠之認知行為。自植入之日起,實 驗組大鼠分別投予安慰劑、不同劑量之PM903(1至25 mg/kg)及 1〇〇 mg/kg之 PMWH。 被動迴避測試之構造 被動迴避測a式係根據避暗實驗法(step-through method) 進 亍(參見 Jarvik Μ. Ε·及 Kopp R. 及ep. (1967) 8 月;21(1):221-224)。將由明箱組成之裝置藉由含有閘門 之分隔牆與暗箱連接。在訓練期中,以下列方法進行獲得 試驗(acquisition trial):使大鼠在明箱中適應2 min,隨後 打開閘門。3秒之後,當大鼠穿過至暗箱中時,傳輸不可 避免之電擊(〇.8mA,3秒)。重複此試驗直至確定獲得。當 大鼠最終留在明箱中300秒以上以避免進入暗箱時可認定 為確定獲得。將大鼠移走並放回至籠中。藉由an〇va分 析資料。(31'0£1/1' with 0,1;3-8;1^〇(161 51650) to locate the lateral ventricle. Insert the cerebral perfusion set into the third lateral ventricle of the rat, and the Alzet osmotic pump The subcutaneous area of the rat's neck was implanted. The surgical area was sutured and the rats were placed in a cage. In the control group (Sham), the Αβ 1-40 solution in the Alzet osmotic pump was 35% acetonitrile / 0.1%. Trifluoroacetic acid replacement. Rats were subjected to passive avoidance testing 8 to 9 days after implantation. The cognitive behavior of the rats was assessed using a Morris water maze 1 to 15 days after implantation. From the experimental group, rats were given placebo, different doses of PM903 (1 to 25 mg/kg) and 1 〇〇mg/kg of PMWH. Passive avoidance test constructed passive avoidance test a-type system according to the dark test method (step-through method) (see Jarvik Μ. Ε· and Kopp R. and ep. (1967) August; 21(1): 221-224). The device consisting of a clear box is separated by a gate. The wall is connected to the black box. During the training period, the acquisition trial is performed in the following manner: the rat is allowed to acclimate in the clear box for 2 min, and then the gate is opened. Thereafter, when the rat passed through to the dark box, an unavoidable electric shock (〇8 mA, 3 seconds) was transmitted. This test was repeated until it was determined to be obtained. When the rat finally stayed in the clear box for more than 300 seconds to avoid entering the dark box Can be determined to be determined. The rats were removed and returned to the cage. The data was analyzed by an〇va.

Morris水迷宮之建構 在神經科學中,Morris水迷宮之設計為測試空間記憶之 行為程序。其係由神經科學家Richard G M〇rrissi984研 發(參見 Morris R. J Neurosci Methods (1984) 1 1 (l)· 47- 115989.doc •27· 1377949 6〇),現今if常用於探測海馬區在形成該空間記憶方面之 作用。 將圓筒狀水槽(直徑為160⑽,深為60 cm)加水至35⑽ 深,並使水溫維持在23±rc。將水池分為四個象限(西 北、西南、東北及東南)。將圓形不鏽鋼救生平台固定於" 西南象限中並隱藏於水面以TI⑽。將視覺線索(例如彩 色形狀)置放於動物視線中的水槽周圍。 接相機置放於水池上方以操取並記錄所受試 仃軌跡之影像。 動物行為之測試 練= = 隻大鼠。將大鼠訓練3天,每天1個訓 =二:期4個循環。在各循環中給予每_大_ 私以I現西南"象限中 平台,則將大鼠引導至平大鼠不能發現救生 秒。藉由電腦追料循環前讓Μ休息15 時* 、,先。己錄包括游泳路徑及到逹平台所用 時間(潛伏時間)之整個 nm 走,並古十算大^ 則式過程。第4天’將救生平台移 限所用時間。ι Γ、.5分鐘内到達"西南”象限及到達其他象 ’卩最㈣次行為測試所獲得之潛伏時間及游 冰距離的資料來表示大 △ 及游 ANOVA分析資料。第于 C憶能力。藉由 記憶。 ㈣表示大鼠之參考空間 測試之結果顯示於圖2中。學習及記憶能力之 結果顯不於圖3中, 、月b刀之 圖4中。由圖2至 L呂測6式之參考記憶結果顯示於 至4可見’對照組(Sham)中之大鼠未顯示認 115989.doc -28· 1377949 知行為障礙,然而用安慰劑(圖中所示之Αβ ι_4〇組)處理之 Αβ 1 -40誘發癡呆症大鼠則顯現嚴重認知行為障礙。結果 發現ΡΜ903(每公斤體重1 ' 5及25毫克)可有效改善Αβ 1_40 誘發癡呆症大鼠之被動迴避及空間記憶。ΡΜ903之有效劑 量為每公斤體重1至25毫克。與陽性對照物(圖中所示之 PMWH組)相比,ΡΜ903之有效劑量需要量減少20倍以上。 【圖式簡單說明】Construction of the Morris Water Maze In neuroscience, the Morris water maze is designed to test the behavior of spatial memory. It was developed by neuroscientist Richard GM〇rrissi984 (see Morris R. J Neurosci Methods (1984) 1 1 (l)· 47- 115989.doc • 27· 1377949 6〇), which is now commonly used to detect hippocampus The role of spatial memory. Add a cylindrical water tank (160 (10) in diameter and 60 cm deep) to a water depth of 35 (10) and maintain the water temperature at 23 ± rc. The pool is divided into four quadrants (north, southwest, northeast, and southeast). Fix the circular stainless steel life-saving platform in the " southwest quadrant and hide it on the water surface with TI(10). Place visual cues (such as colored shapes) around the sink in the animal's line of sight. The camera is placed above the pool to capture and record the image of the test track. Test of animal behavior Practice = = only rats. Rats were trained for 3 days, 1 training per day = 2: 4 cycles. In each cycle, each of the _ large _ private I was in the southwest " quadrant platform, and the rats were guided to the flat rats and no lifesaving seconds were found. Let the rest of the 15 15 hours by the computer before the cycle. *, first. It has recorded the entire nm path including the swimming path and the time (latency) used for the platform, and the ancient ten is a large process. Day 4 'The time taken to move the life-saving platform. ι Γ,. Within 5 minutes to reach the "Southwestern" quadrant and to reach other data such as the latency time and the ice travel distance obtained by the '卩 most (four) behavior test to indicate the large △ and ANOVA analysis data. By memory. (4) The results of the reference space test of the rat are shown in Figure 2. The results of learning and memory ability are not shown in Figure 3, Figure 4 of the monthly b-knife. From Figure 2 to L-L The results of the reference memory of type 6 were shown to be seen in the 'sham' group. The rats in the control group (Sham) did not show recognition of 115989.doc -28·1377949, but with placebo (the Αβ ι_4〇 group shown in the figure) The treatment of Αβ 1 -40 induced dementia rats showed severe cognitive behavior disorder. It was found that ΡΜ903 (1 '5 and 25 mg/kg body weight) can effectively improve the passive avoidance and spatial memory of Αβ 1_40 induced dementia rats.ΡΜ903 The effective dose is 1 to 25 mg per kg of body weight. Compared with the positive control (the PMWH group shown in the figure), the effective dose of ΡΜ903 is reduced by more than 20 times. [Simplified explanation]

囷1顯示(Α) : 2,3,5,4'-四羥基二苯乙烯-;2-〇-p-D-糠苷 (TSG) ; (B):兒茶素;(C):大黃素(EMD);及(D):大黃 素-8-〇_p_D_糖苷(Em〇g)之化學結構。 圖2顯示被動迴避測試之結果。 圊3顯示水迷宮測試之空間操縱能力的結果。 圖4顯示水迷宮測試之工作記憶的結果。 115989.doc 29-囷1 shows (Α): 2,3,5,4'-tetrahydroxystilbene-;2-〇-pD-purine glycoside (TSG); (B): catechin; (C): emodin (EMD); and (D): chemical structure of emodin-8-〇_p_D_glycoside (Em〇g). Figure 2 shows the results of the passive avoidance test.圊3 shows the results of the space maneuverability of the water maze test. Figure 4 shows the results of the working memory of the water maze test. 115989.doc 29-

Claims (1)

第097122258號專利申請案 士 tb 4_叙金心1 々Ar na 从· <_ · ίρυ,/κζζ:>δ现寻;f’J 甲請累 J>« 、申請專糊:w娜嶋柳 〜種製備何首烏(p0!yg0num muitifl〇rum)萃取物~^~^- 法,其包含以下步驟: a) 以約1〇至30 Wv%之乙醇溶液或甲醇萃取何首烏草 藥以獲得何首烏粗萃取物; b) 以水稀釋步驟a)獲得之粗萃取物以獲得具有約2至5 v/v%之最終醇濃度的經稀釋粗萃取物; C)將該步驟b)之經稀釋粗萃取物裝入樹脂管柱中; )以一或多種約1〇至1〇〇 ν/ν〇/β2醇溶液自該管柱沖提 何首烏萃取物;及 2. 4. e)收集該經沖提之沖提份並將其合併以獲得提純之何 首烏萃取物。 如凊求項1之方法’其中該何首烏草藥為乾燥或經加工 之何首烏草藥。 如π求項1之方法,其中該醇溶液為乙醇、.曱醇或異丙 醇溶液。 月求項1之方法,其中該樹脂為大孔樹脂或凝膠樹 5·如請求項4夕士、α <方法,其中該大孔樹脂為DiAION HP. 脂 6.如 脂 20樹 月求項4之方法’其中該凝膠樹脂為Sephadex LH-20樹 7·如請求項1夕士、 万法’其中該步驟a)之萃取係在室溫下進 行0 115989-1010627.doc 丄:wmy 8·如請求項8之方i ♦ 乃去,其中該步驟a)之举取係在約5.3之pH 值下進行。 9. 如請求項1之古、、+ 法’其中該步驟d)之醇溶液具有約30至70 v/v%之濃度。 A U項1之方法’其中該步驟d)之醇溶液具有約35至50 v/v%之濃度。 11. 如清求項1之方. 〈万法’其中該步驟d)之醇溶液為50 v/v%之 甲醇溶液。 12. 如清求項丨之方法,其中該步驟幻之醇溶液為約h v/v% 之乙醇溶液。 13. 如凊求項1之方法,其中該步驟旬之醇溶液為約% ν/ν% 之乙醇溶液。 14. 如凊求項1之方法,其中該步驟e)中所獲得之何首烏萃取 物包含約65至85 w/w〇/0之2,3,5,4,_四羥基二笨乙烤_2·〇-ρ_ D-糖音(TS.G)及約5至l〇w/w%之兒茶素。 15. —種藉由如請求項丨之方法製備之何首烏萃取物。 16. 如請求項15之何首烏萃取物,其包含約“至以说~%之 TSG及約5至10 w/w%之兒茶素。 17. 如請求項15之何首烏萃取物,其包含小於約〇 5之 大黃素及小於約0.2 w/w〇/。之大黃素·8_〇_p_D糖芽。 18. —種醫藥組合物,其包含治療有效劑量之如請求項”之 何首烏萃取物及視情況醫藥學上可接受之載劑、稀釋劑 或賦形劑》 19. 如請求項18之醫藥組合物,其另外包含一或多種其他抗 I15989-1010627.doc 1377949 癡呆症藥劑。 20. —種如請求項18之醫藥組合物之用途,其係用於製備用 以預防或治療癡呆症之醫藥品。 21. 如請求項20之用途,其中該癡呆症係選自由老化相關之 癡呆症、阿茲海默氏症(Alzheimer,s disease)、如管性礙 呆症及輕型精神及智力病症組成之群。 22.Patent application No. 097122258, tb 4_ Syrian gold 1 々Ar na From · <_ · ίρυ, /κζζ:>δ is looking for; f'J A please tired J>«, apply for special paste: wna The preparation of the Polygonum multiflorum (p0!yg0num muitifl〇rum) extract ~^~^- method comprises the following steps: a) extracting Polygonum multiflorum with about 1〇 to 30 Wv% ethanol solution or methanol to obtain Polygonum multiflorum Extracting; b) diluting the crude extract obtained in step a) with water to obtain a diluted crude extract having a final alcohol concentration of about 2 to 5 v/v%; C) diluting the crude extract of step b) Loading the resin column;) extracting the extract of Polygonum multiflorum from the column with one or more alcohol solutions of about 1 Torr to 1 〇〇 ν / ν 〇 / β 2; and 2. 4. e) collecting the extracted The extracts were combined and combined to obtain purified Polygonum multiflorum extract. For example, the method of claim 1 wherein the Polygonum multiflorum herb is a dried or processed Polygonum multiflorum herb. A method of claim 1, wherein the alcohol solution is an ethanol, .anol or isopropanol solution. The method of claim 1, wherein the resin is a macroporous resin or a gel tree. 5. The method of claim 4, wherein the macroporous resin is DiAION HP. The method of item 4, wherein the gel resin is Sephadex LH-20 tree 7. The extraction system of the step 1) of claim 1 is carried out at room temperature. 0 115989-1010627.doc 丄:wmy 8. If the claim i is ♦, the step a) is carried out at a pH of about 5.3. 9. The alcohol solution of claim 1, wherein the alcohol solution of step d) has a concentration of from about 30 to 70 v/v%. The method of A U item 1 wherein the alcohol solution of step d) has a concentration of about 35 to 50 v/v%. 11. For example, in the case of the item 1 of the formula, the alcohol solution of the step d) is a 50 v/v% methanol solution. 12. The method of claim 1, wherein the step of the alcohol solution is an ethanol solution of about h v/v%. 13. The method of claim 1, wherein the alcohol solution in the step is an ethanol solution of about % ν / ν %. 14. The method of claim 1, wherein the extract of Polygonum multiflorum obtained in step e) comprises about 2, 3, 5, 4, _ tetrahydroxy diphenyl bromide of about 65 to 85 w/w 〇 /0 2·〇-ρ_ D-sugar tone (TS.G) and about 5 to l〇w/w% of catechin. 15. An extract of Polygonum multiflorum prepared by the method of claim 丨. 16. The extract of Polygonum multiflorum according to claim 15 which comprises about "to a TSG of ~% and a catechin of about 5 to 10 w/w%." 17. The extract of Polygonum multiflorum according to claim 15 which comprises less than大 之 之 emodin and less than about 0.2 w / w 〇 / emodin · 8_ 〇 _p_D sugar buds. 18. A pharmaceutical composition comprising a therapeutically effective dose of the claimant Extracts and, where appropriate, pharmaceutically acceptable carriers, diluents or excipients 19. The pharmaceutical composition of claim 18, which additionally comprises one or more additional anti-I15989-1010627.doc 1377949 dementia agents. 20. Use of a pharmaceutical composition according to claim 18 for the manufacture of a medicament for the prevention or treatment of dementia. 21. The use of claim 20, wherein the dementia is selected from the group consisting of aging-related dementia, Alzheimer's disease, such as schizophrenia, and mild mental and intellectual conditions. . twenty two. 如請求項2〇之用途’其中該醫藥品係 重約1至25毫克之何首烏萃取物。 用於投予每公斤體The use of claim 2 wherein the pharmaceutical product is about 1 to 25 mg of Polygonum multiflorum extract. For every kilogram of body I15989-1010627.docI15989-1010627.doc
TW97122258A 2008-06-13 2008-06-13 A chinese herb extract for treating dementia and preparation method thereof TWI377949B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW97122258A TWI377949B (en) 2008-06-13 2008-06-13 A chinese herb extract for treating dementia and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW97122258A TWI377949B (en) 2008-06-13 2008-06-13 A chinese herb extract for treating dementia and preparation method thereof

Publications (2)

Publication Number Publication Date
TW200950795A TW200950795A (en) 2009-12-16
TWI377949B true TWI377949B (en) 2012-12-01

Family

ID=44871493

Family Applications (1)

Application Number Title Priority Date Filing Date
TW97122258A TWI377949B (en) 2008-06-13 2008-06-13 A chinese herb extract for treating dementia and preparation method thereof

Country Status (1)

Country Link
TW (1) TWI377949B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104945450B (en) * 2015-07-17 2018-05-29 湖南杰萃生物技术有限公司 A kind of method that Stibene-glucoside is extracted from the vine of multiflower knotweed

Also Published As

Publication number Publication date
TW200950795A (en) 2009-12-16

Similar Documents

Publication Publication Date Title
KR101445010B1 (en) Antiphlogistic, antioncotic and analgesic chinese herbal composition, preparative method and usage thereof
US7824714B2 (en) Chinese herb extract for treating dementia and preparation method thereof
KR101189191B1 (en) Composition comprising longan arillus extract or mixed extracts comprising the same for neurodegenerative diseases
JP2024010025A (en) Compositions, methods and medical compositions for treating liver and maintaining health of liver
KR20100042337A (en) The composition of traditional oriental medicines for reheumatoid arthritis and the method of preparing medicine for it
EP2117560B1 (en) A composition for selective serotonin reuptake inhibition and process thereof
KR101341693B1 (en) Composition comprising the extract of herbs for preventing or treating neurodegenerative disorders
KR101934794B1 (en) Composition for preventing, improving or treating atopic dermatitis comprising extract mixture of Diospyros lotus leaf and grape fruit stem as effective component
EP3235503B1 (en) Composition containing mixed extract of mulberry and poria cocos bark for preventing, improving or treating neurodegenerative disorders
US10561678B2 (en) Composition for treating neuropathy, process and method of treatment thereof
KR101997335B1 (en) Composition comprising citrale or as active ingredients for muscle strengthening, development, differentiation, regeneration or inhibiting muscle atrophy
WO1986005180A1 (en) Novel tannin composition
CN103070927A (en) New usages of lotus plumule and alkaloid thereof and derivative thereof
TWI377949B (en) A chinese herb extract for treating dementia and preparation method thereof
KR20200091925A (en) Composition comprising a horse chestnut extract
KR101029699B1 (en) The composition for the improvements and prevention of the symptoms in the alzheimer's disease comprising the extracts from oriental herb medicines
CN115461051B (en) Pharmaceutical composition and use thereof for treating parkinson's disease
KR20140108104A (en) Compositions comprising the combined extract of Artemisia iwayomogi and Curcuma longa for treating, inhibiting or preventing obesity-related disease
CN102670865A (en) Process for extracting active ingredients of American eleutherine rhizome
CN110279748A (en) A kind of application of Cortex Magnoliae Officinalis essential oil
KR20070013640A (en) Therapeutic agent for narcotics addiction
WO2016017840A1 (en) Pain relieving or therapeutic agent containing gastrodia elata extract
CN104130232B (en) The method of purification of a kind of EGCG and the EGCG of acquisition and pharmaceutical composition
KR20120060678A (en) Composition for treating and preventing Alzheimer's disease containing extract of Schizandra seed
KR20040011236A (en) Anti-allergic composition containing arctium lappa seed extract